Business
Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference
Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that an abstract has been accepted at the American Thoracic Society (ATS) 2025 International Conference taking place May 18-21, 2025 in San Francisco, CA.
About this update from Rein Therapeutics, Inc.
[{"type":"text","content":"AUSTIN, Texas, April 28, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that an abstract has been accepted at the American Thoracic Society (ATS) 2025 International Conference taking place May 18-21, 2025 in San Francisco, CA.","length":451,"tagName":"p"},{"type":"image","alt":"Rein Logo (PRNewsfoto/Rein Therapeutics, Inc.)","displaySize":"","headline":null,"caption":"Rein Logo (PRNewsfoto/Rein Therapeutics, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/21d12d0173749cab9897840a84c884b9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WGIrWF_9jgkFNz.d57uEvw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/21d12d0173749cab9897840a84c884b9","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/2595086/Rein_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Details of the poster presentation are as follows:","length":50,"tagName":"p"},{"type":"text","content":"Presentation Title: Evaluating Alveolar Regenerative Properties of Caveolin Scaffolding Peptides (CSD) in Three Dimensional (3D) Alveolospheres from IPF and Normal Donor Lung Samples Poster #: P1463Session: B75 Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and FibrosisDate & Time: Monday, May 19, 2025, at 11:30 AM PT/ 2:30 PM ET","length":374,"tagName":"p"},{"type":"text","content":"About Rein Therapeutics","length":23,"tagName":"p"},{"type":"text","content":"Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. A Phase 2 clinical trial of LTI-03 for the treatment of idiopathic pulmonary fibrosis is anticipated to be initiated in the first half of this year. Rein's second product candidate, LTI-0...